These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35606799)

  • 1. Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China.
    Wang JL; Fu YD; Gao YH; Li XP; Xiong Q; Li R; Hou B; Huang RS; Wang JF; Zhang JK; Lv JL; Zhang C; Li HW
    Genes Environ; 2022 May; 44(1):17. PubMed ID: 35606799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of EGFR mutation and clinical features of lung cancer in Yunnan].
    Zhou YC; Lin YP; Li Q; Ma LY; Liu X; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Dai M; Zhang Q
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):729-734. PubMed ID: 32988154
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mutation status of epidermal growth factor receptor and KRAS gene in non-small cell lung cancers at Xuanwei regions of Yunnan Province].
    Yang CS; Pan XY; Feng Q; Wang YY; Xu WM; Jiang T; Wang L; Yang JL; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):226-30. PubMed ID: 27033384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.
    Lin Y; Chen L; Li R; Liu X; Li Q; Cai J; Du Y; Zhao G; Wang X; Shen Z; Liao Y; Chen Y; Xie L; Zhou Y; Huang Y
    Front Oncol; 2023; 13():1156647. PubMed ID: 37881485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
    Zhou Y; Yang Y; Yang C; Chen Y; Yang C; Du Y; Zhao G; Guo Y; Ye L; Huang Y
    Oncotarget; 2017 Feb; 8(9):15023-15033. PubMed ID: 28107191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct
    Lv L; Liu Z; Liu Y; Zhang W; Jiang L; Li T; Lu X; Lei X; Liang W; Lin J
    Front Oncol; 2020; 10():519073. PubMed ID: 33224870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China.
    Zhou Y; Ge F; Du Y; Li Q; Cai J; Liu X; Guo Y; Shen Z; Duan L; Huang Z; Yao F; Zhu C; Shi H; Huang Y
    Front Oncol; 2021; 11():644895. PubMed ID: 33928034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China.
    Chen Y; Ye L; Stanford RR; Zhang D; Zhang X; Wei W
    Mol Clin Oncol; 2016 May; 4(5):749-755. PubMed ID: 27123274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
    [No Abstract]   [Full Text] [Related]  

  • 10. Genomic profiling reveals non-small cell lung cancer with common mutations of
    Bi X; Song P; Wang C; Zhang X; Liu C
    Transl Cancer Res; 2022 May; 11(5):1423-1428. PubMed ID: 35706785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
    Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
    J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful therapy of a critically ill non-small cell lung cancer patient with compound mutations in
    Pan X; Shi M
    Heliyon; 2024 Mar; 10(5):e27106. PubMed ID: 38439894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
    Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.
    Zhu X; Bai Q; Lu Y; Qi P; Ding J; Wang J; Zhou X
    Target Oncol; 2017 Feb; 12(1):81-88. PubMed ID: 27538584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients.
    Guo G; Li G; Liu Y; Li H; Guo Q; Liu J; Yang X; Shou T; Shi Y
    Front Oncol; 2021; 11():621422. PubMed ID: 33889543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.
    Ma Y; Li Q; Du Y; Chen W; Zhao G; Liu X; Li H; Liu J; Shen Z; Ma L; Zhou Y
    Cancer Manag Res; 2020; 12():10861-10874. PubMed ID: 33149691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the conformational dynamics and thermodynamics of
    Wang JL; Liu MS; Fu YD; Kan QB; Li CY; Ma R; Fang ZW; Liu HX; Li MX; Lv JL; Sang P; Zhang C; Li HW
    Open Life Sci; 2023; 18(1):20220768. PubMed ID: 38035047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
    Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
    Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD
    Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.